{"entity":{"id":"pgdx-elio-tissue-complete-cdx","kind":"drug","name":"PGDx elio tissue complete CDx","aka":[],"tldr":"A tumour sequencing test approved in July 2026 as a companion diagnostic that finds BRAF V600E or V600K in melanoma, the mutations BRAF-targeted drugs act on.","summary":"Personal Genome Diagnostics, Inc. received FDA approval for PGDx elio tissue complete CDx on 30 July 2026 (PMA P250036). The FDA approval statement describes a qualitative, hybridisation-capture sequencing test on tumour tissue DNA that detects single-nucleotide variants, small insertions and deletions, copy number amplifications and translocations, intended as a companion diagnostic in melanoma. The FDA companion diagnostic list gives its claim as identifying melanoma with BRAF V600E and V600K for two groups of medicines approved by the FDA for that indication. The BRAF inhibitors it lists are dabrafenib (Tafinlar) and vemurafenib (Zelboraf); the BRAF and MEK inhibitor combinations it lists are cobimetinib (Cotellic) with vemurafenib, encorafenib (Braftovi) with binimetinib (Mektovi), and dabrafenib with trametinib (Mekinist).","status":"approved","asOf":"2026-11-19","links":[{"label":"openFDA PMA record P250036 (original approval)","url":"https://api.fda.gov/device/pma.json?search=pma_number:P250036+AND+supplement_number:%22%22"},{"label":"FDA PMA P250036","url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250036"},{"label":"FDA: List of FDA-Authorized Companion Diagnostic Devices","url":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools"}],"tags":["test"],"related":["cobas-4800-braf-v600","thxid-braf"],"cancers":["melanoma"],"sections":[],"technologies":["companion-diagnostic"],"targets":["braf"],"drugs":["dabrafenib","vemurafenib","cobimetinib","encorafenib","binimetinib","trametinib"],"companies":[],"institutions":[],"pathways":[],"terms":["ngs","companion-diagnostic-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"PGDx elio tissue complete CDx","modality":"Tissue NGS companion diagnostic test (BRAF V600E and V600K in melanoma)","mechanism":"Hybridisation-capture next-generation sequencing of DNA from formalin-fixed, paraffin-embedded tumour tissue; the targeted panel detects single-nucleotide variants, small insertions and deletions, copy number amplifications and translocations.","approvals":[{"region":"US","year":2026,"indication":"BRAF V600E and V600K in melanoma, for BRAF inhibitors and BRAF and MEK inhibitor combinations approved by the FDA for that indication (group labelling)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pgdx-elio-tissue-complete-cdx/","neighbours":{"drug":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/"},{"id":"cobas-4800-braf-v600","kind":"drug","name":"cobas 4800 BRAF V600 Mutation Test","route":"/drugs/cobas-4800-braf-v600/"},{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/"},{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"},{"id":"thxid-braf","kind":"drug","name":"THxID BRAF Kit","route":"/drugs/thxid-braf/"},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"}],"term":[{"id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"}]}}